Publications by authors named "Benjamin D Crossley"

A highly robust immobilized [Cp*IrCl2]2 precatalyst on Wang resin for transfer hydrogenation, which can be recycled up to 30 times, was studied using a novel combination of X-ray absorption spectroscopy (XAS) at Ir L3-edge, Cl K-edge, and K K-edge. These culminate in in situ XAS experiments that link structural changes of the Ir complex with its catalytic activity and its deactivation. Mercury poisoning and "hot filtration" experiments ruled out leached Ir as the active catalyst.

View Article and Find Full Text PDF

Group IV metal complexes have previously shown promise as novel anticancer agents. Here, we discuss the mechanistic and cytotoxic nature of a series of group IV β-diketonate coordination complexes. Clear evidence that the ligands are exchangeable on the metal centre and that the β-diketonate ligands can act as potential drug delivery vehicles of the group IV metal ions was obtained.

View Article and Find Full Text PDF

Novel rhodium, iridium, and ruthenium half-sandwich complexes containing (N,N)-bound picolinamide ligands have been prepared for use as anticancer agents. The complexes show promising cytotoxicities, with the presence, position, and number of halides having a significant effect on the corresponding IC50 values. One ruthenium complex was found to be more cytotoxic than cisplatin on HT-29 and MCF-7 cells after 5 days and 1 h, respectively, and it remains active with MCF-7 cells even under hypoxic conditions, making it a promising candidate for in vivo studies.

View Article and Find Full Text PDF

This paper provides a viable, reproducible and robust method for immobilising hydroxyl tethered iridium-rhodium complexes. The materials have been shown to be both effective and recyclable in the process of catalytic transfer hydrogenation with minimal metal leaching.

View Article and Find Full Text PDF

A diverse library of cationic silver complexes bearing bis(N-heterocyclic carbene) ligands have been prepared which exhibit cytotoxicity comparable to cisplatin against the adenocarcinomas MCF7 and DLD1. Bidentate ligands show enhanced cytotoxicity over monodentate and macrocyclic ligands.

View Article and Find Full Text PDF